The DME phase 2 results were not quite as good as expected but there was good reasons for that which they need to explore in another phase 2. Same product. That's where the additional funding would have been useful.
Funding wise, I don't think they are far off from full trial funding. May need a small amount towards the end. I'm not concerned with a small CR. They may even have a partner at that point. Unfortunately, they could not get that partnership/deal to derisk and fund this P3 trial. This, in hindsight, has been a large contributor to the SP slide. No real chance of a deal now until after P3 or close to P3 results. That's too long for most investors.
OPT Price at posting:
$1.19 Sentiment: None Disclosure: Held
(20min delay)